Literature DB >> 25054046

Magnetic resonance imaging shrinkage patterns following neoadjuvant chemotherapy for breast carcinomas with an emphasis on the radiopathological correlations.

Kaori Tomida1, Mitsuaki Ishida2, Tomoko Umeda1, Sachiko Sakai1, Yuki Kawai1, Tsuyoshi Mori1, Yoshihiro Kubota1, Eiji Mekata1, Shigeyuki Naka1, Hajime Abe1, Hidetoshi Okabe2, Tohru Tani1.   

Abstract

Preoperative neoadjuvant chemotherapy (NAC) is considered to be the standard treatment for locally-advanced breast carcinomas. Obtaining precise information regarding the tumor extent and distribution by imaging modalities to assess the success of breast-conserving surgery following NAC is extremely important. Analysis of the detailed radiopathological correlation of magnetic resonance imaging (MRI) following NAC has not been reported previously. The MRI and histopathological shrinkage patterns of residual breast carcinomas in 27 consecutive cases were analyzed following NAC and classified into five categories: Types I and II (concentric shrinkage with and without surrounding lesions, respectively); type III (shrinkage with residual multinodular lesions); type IV (diffuse contrast enhancement in whole quadrant); and non-visualization. The present study clearly demonstrated that the most common MRI shrinkage pattern was type I (11 cases), followed by type II and non-visualization, and the most common histopathological shrinkage pattern was type II (11 cases), followed by type III (8 cases). The concordance rate between MRI and pathological patterns was 48% and the worst concordance MRI pattern was type I. MRI is considered to be a useful method for evaluation of the residual carcinoma following NAC. However, the concordance rate was low in the MRI pattern I cases and tiny foci of residual carcinoma were present in half of the non-visualization cases, as shown by MRI. Therefore, the tumor extent must be completely resected for patients who undergo NAC, and postoperative radiation may be important for preventing local recurrence of breast carcinoma.

Entities:  

Keywords:  breast cancer; magnetic resonance imaging; neoadjuvant chemotherapy; shrinkage pattern

Year:  2014        PMID: 25054046      PMCID: PMC4106740          DOI: 10.3892/mco.2014.333

Source DB:  PubMed          Journal:  Mol Clin Oncol        ISSN: 2049-9450


  13 in total

Review 1.  Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer. Seventh International Conference on Adjuvant Therapy of Primary Breast Cancer.

Authors:  A Goldhirsch; J H Glick; R D Gelber; A S Coates; H J Senn
Journal:  J Clin Oncol       Date:  2001-09-15       Impact factor: 44.544

2.  MRI of breast cancer: influence of chemotherapy on sensitivity.

Authors:  A Rieber; H Zeitler; H Rosenthal; J Görich; R Kreienberg; H J Brambs; R Tomczak
Journal:  Br J Radiol       Date:  1997-05       Impact factor: 3.039

3.  Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis.

Authors:  Davide Mauri; Nicholas Pavlidis; John P A Ioannidis
Journal:  J Natl Cancer Inst       Date:  2005-02-02       Impact factor: 13.506

Review 4.  Preoperative (neoadjuvant) chemotherapy in patients with breast cancer.

Authors:  E P Mamounas; B Fisher
Journal:  Semin Oncol       Date:  2001-08       Impact factor: 4.929

5.  Breast-conserving surgery after chemotherapy: value of MDCT for determining tumor distribution and shrinkage pattern.

Authors:  Mitsuhiro Tozaki; Tadashi Kobayashi; Shinji Uno; Keisuke Aiba; Hiroshi Takeyama; Hisashi Shioya; Isao Tabei; Yasuo Toriumi; Masafumi Suzuki; Kunihiko Fukuda
Journal:  AJR Am J Roentgenol       Date:  2006-02       Impact factor: 3.959

6.  Effect of preoperative chemotherapy on the outcome of women with operable breast cancer.

Authors:  B Fisher; J Bryant; N Wolmark; E Mamounas; A Brown; E R Fisher; D L Wickerham; M Begovic; A DeCillis; A Robidoux; R G Margolese; A B Cruz; J L Hoehn; A W Lees; N V Dimitrov; H D Bear
Journal:  J Clin Oncol       Date:  1998-08       Impact factor: 44.544

7.  A new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survival.

Authors:  Keith N Ogston; Iain D Miller; Simon Payne; Andrew W Hutcheon; Tarun K Sarkar; Ian Smith; A Schofield; Steven D Heys
Journal:  Breast       Date:  2003-10       Impact factor: 4.380

8.  Identification of residual breast carcinoma following neoadjuvant chemotherapy: diffusion-weighted imaging--comparison with contrast-enhanced MR imaging and pathologic findings.

Authors:  Reiko Woodhams; Satoko Kakita; Hirofumi Hata; Keiichi Iwabuchi; Masaru Kuranami; Shiva Gautam; Hiroto Hatabu; Shinichi Kan; Carolyn Mountford
Journal:  Radiology       Date:  2010-02       Impact factor: 11.105

9.  Residual breast cancer diagnosed by MRI in patients receiving neoadjuvant chemotherapy with and without bevacizumab.

Authors:  Shadfar Bahri; Jeon-Hor Chen; Rita S Mehta; Philip M Carpenter; Ke Nie; Soon-Young Kwon; Hon J Yu; Orhan Nalcioglu; Min-Ying Su
Journal:  Ann Surg Oncol       Date:  2009-03-31       Impact factor: 5.344

Review 10.  Preoperative chemotherapy for women with operable breast cancer.

Authors:  J S D Mieog; J A van der Hage; C J H van de Velde
Journal:  Cochrane Database Syst Rev       Date:  2007-04-18
View more
  7 in total

Review 1.  Biomarkers of residual disease after neoadjuvant therapy for breast cancer.

Authors:  Frederique Penault-Llorca; Nina Radosevic-Robin
Journal:  Nat Rev Clin Oncol       Date:  2016-02-09       Impact factor: 66.675

Review 2.  How to use magnetic resonance imaging following neoadjuvant chemotherapy in locally advanced breast cancer.

Authors:  Elissa R Price; Jasmine Wong; Rita Mukhtar; Nola Hylton; Laura J Esserman
Journal:  World J Clin Cases       Date:  2015-07-16       Impact factor: 1.337

Review 3.  Neoadjuvant chemotherapy in oral cancers: Selecting the right patients.

Authors:  S Vishak; Bharath Rangarajan; Vikram D Kekatpure
Journal:  Indian J Med Paediatr Oncol       Date:  2015 Jul-Sep

Review 4.  Evaluation of the Efficacy of Neoadjuvant Chemotherapy for Breast Cancer.

Authors:  Huan Wang; Xiaoyun Mao
Journal:  Drug Des Devel Ther       Date:  2020-06-18       Impact factor: 4.162

5.  Meta-Analysis of Shrinkage Mode After Neoadjuvant Chemotherapy for Breast Cancers: Association With Hormonal Receptor.

Authors:  Chun-Hui Zheng; Kai Xu; Wen-Ping Shan; Ya-Kun Zhang; Zhi-De Su; Xiang-Jin Gao; Yu-Jue Wang; Jian-Yu Qi; Xiao-Yan Ding; Chun-Ping Wang; Yong-Sheng Wang
Journal:  Front Oncol       Date:  2022-04-04       Impact factor: 5.738

6.  Direct comparison of magnetic resonance imaging and pathological shrinkage patterns of triple-negative breast cancer after neoadjuvant chemotherapy.

Authors:  Katsuhiro Yoshikawa; Mitsuaki Ishida; Naoki Kan; Hirotsugu Yanai; Koji Tsuta; Mitsugu Sekimoto; Tomoharu Sugie
Journal:  World J Surg Oncol       Date:  2020-07-21       Impact factor: 2.754

7.  Neoadjuvant systemic therapy does not compromise local control after breast-conserving surgery: a single-center, propensity score matching study in China.

Authors:  Fan Yang; Si-Yu Wu; Miao Mo; Qin Xiao; Xia Yang; Ying-Ying Liu; Jian-Wei Li; Zhi-Ming Shao; Guang-Yu Liu
Journal:  Transl Cancer Res       Date:  2020-01       Impact factor: 1.241

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.